We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
GSTT2
HPA
RESOURCES
  • TISSUE
  • BRAIN
  • SINGLE CELL
  • SUBCELLULAR
  • CANCER
  • BLOOD
  • CELL LINE
  • STRUCTURE & INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Antibody panel
Tissue
Main location
Patient ID
Annotation
Tissue
Category
Tau score
Cluster
Reliability
Brain region
Category
Tau score
Brain region
Category
Tau score
Brain region
Category
Tau score
Cluster
Reliability
Tissue
Cell type
Enrichment
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell lineage
Category
Tau score
Cluster
Cluster
Location
Searches
Location
Cell line
Class
Type
Phase
Reliability
Cancer
Prognosis
Cancer
Category
Cancer
Category
Tau score
Cluster
Variants
Interacting gene (ensg_id)
Type
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Data type
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • SUBCELL

  • CANCER

  • BLOOD

  • CELL LINE

  • STRUCT & INT

  • GSTT2
CANCER GLIOMA Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
GBM TCGA GBM VALIDATION PROTEIN GBM CPTAC PROTEIN EXPRESSION
ANTIBODIES
AND
VALIDATION
Dictionary
Glioma
Human cancer
Glioblastoma multiforme
GLIOBLASTOMA MULTIFORME (TCGA) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
GLIOBLASTOMA MULTIFORME (VALIDATION) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples 110
Samples
Sample ID Sample type nRPX
CPT0206330003 Tumor N/A
CPT0186100003 Tumor N/A
CPT0123530003 Tumor N/A
CPT0201710003 Tumor N/A
CPT0216920008 Tumor N/A
CPT0218890004 Tumor N/A
CPT0224390004 Tumor N/A
CPT0204390003 Normal N/A
CPT0093590003 Tumor N/A
CPT0167750004 Tumor N/A
CPT0204400003 Normal N/A
CPT0079790003 Tumor N/A
CPT0218690004 Tumor N/A
CPT0204370003 Normal N/A
CPT0161730003 Tumor N/A
CPT0168720003 Tumor N/A
CPT0206880003 Tumor N/A
CPT0189650004 Tumor N/A
CPT0204350003 Normal N/A
CPT0168380003 Tumor N/A
CPT0205890003 Tumor N/A
CPT0217880003 Tumor N/A
CPT0206560003 Tumor N/A
CPT0087680003 Tumor N/A
CPT0206000004 Tumor N/A
CPT0218670003 Tumor N/A
CPT0204340003 Normal N/A
CPT0189850004 Tumor N/A
CPT0224330003 Tumor N/A
CPT0218330004 Tumor N/A
CPT0167640003 Tumor N/A
CPT0002410011 Tumor N/A
CPT0093450003 Tumor N/A
CPT0206110003 Tumor N/A
CPT0217430008 Tumor N/A
CPT0217000004 Tumor N/A
CPT0196850003 Tumor N/A
CPT0189250003 Tumor N/A
CPT0189570004 Tumor N/A
CPT0162020003 Tumor N/A
CPT0167530003 Tumor N/A
CPT0207030003 Tumor N/A
CPT0127420003 Tumor N/A
CPT0205670004 Tumor N/A
CPT0208980003 Tumor N/A
CPT0206780003 Tumor N/A
CPT0182500003 Tumor N/A
CPT0217710008 Tumor N/A
CPT0168830003 Tumor N/A
CPT0182550003 Tumor N/A
CPT0189460003 Tumor N/A
CPT0167860004 Tumor N/A
CPT0125220003 Tumor N/A
CPT0171580008 Tumor N/A
CPT0087730003 Tumor N/A
CPT0104330003 Tumor N/A
CPT0168590003 Tumor N/A
CPT0205450004 Tumor N/A
CPT0219080004 Tumor N/A
CPT0087570003 Tumor N/A
CPT0162140003 Tumor N/A
CPT0175060003 Tumor N/A
CPT0205780003 Tumor N/A
CPT0218960004 Tumor N/A
CPT0064650003 Tumor N/A
CPT0125570003 Tumor N/A
CPT0190360004 Tumor N/A
CPT0206670004 Tumor N/A
CPT0204380003 Normal N/A
CPT0092440003 Tumor N/A
CPT0162100003 Tumor N/A
CPT0221180003 Tumor N/A
CPT0225760003 Tumor N/A
CPT0093510003 Tumor N/A
CPT0190240004 Tumor N/A
CPT0228220003 Tumor N/A
CPT0204410003 Normal N/A
CPT0224540004 Tumor N/A
CPT0209440003 Tumor N/A
CPT0089150003 Tumor N/A
CPT0204360003 Normal N/A
CPT0168080003 Tumor N/A
CPT0078580003 Tumor N/A
CPT0127480003 Tumor N/A
CPT0204420003 Normal N/A
CPT0218830004 Tumor N/A
CPT0225730003 Tumor N/A
CPT0093360003 Tumor N/A
CPT0168270003 Tumor N/A
CPT0206450003 Tumor N/A
CPT0207090003 Tumor N/A
CPT0104220003 Tumor N/A
CPT0224600003 Tumor N/A
CPT0087950003 Tumor N/A
CPT0204330003 Normal N/A
CPT0199770003 Tumor N/A
CPT0205570003 Tumor N/A
CPT0093550003 Tumor N/A
CPT0167970003 Tumor N/A
CPT0182580003 Tumor N/A
CPT0168480003 Tumor N/A
CPT0206230003 Tumor N/A
CPT0189750004 Tumor N/A
CPT0217100003 Tumor N/A
CPT0064890003 Tumor N/A
CPT0217190003 Tumor N/A
CPT0218770003 Tumor N/A
CPT0125510003 Tumor N/A
CPT0217060003 Tumor N/A
CPT0071100003 Tumor N/A
Show allShow less
GLIOMA - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA000750
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Glioma, malignant, High grade
Glioma, malignant, Low grade

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org